Physician profile
Sharon Miller
NPI 1700963378
$13,458.20
in general payments reported to CMS, 2019-2025
56 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,266 · 2020: $2,420 · 2021: $2,143 · 2022: $2,478 · 2023: $2,913 · 2024: $1,039 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082 · Gift: $59.40 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.37 |
| Gift | $59.40 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,054.92 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,706.87 | 2019-2024 | |
| Lilly USA, LLC | $1,535.78 | 2019-2024 | Mounjaro, Jardiance, Baqsimi |
| Mannkind Corporation | $1,052.75 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $733.20 | 2020-2023 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.37 | 2019-2024 | Jardiance, Tradjenta, Trijardy Xr |
| Abbott Laboratories | $503.87 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $423.61 | 2019-2024 | Korlym |
| Abbvie INC. | $414.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $409.95 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $379.97 | 2021-2024 | |
| Amgen INC. | $323.64 | 2020-2024 | Repatha, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $318.72 | 2019-2021 | |
| Dexcom, INC. | $250.82 | 2021-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $238.90 | 2019-2023 | Tymlos |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.